New agents in chronic lymphocytic leukemia

Current Treatment Options in Oncology

Volumn 7, Issue 3, 2006, Pages 200-212

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ALEMTUZUMAB; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; APOLIZUMAB; BENDAMUSTINE; BRYOSTATIN 1; CD20 ANTIGEN; CD40 LIGAND; CD52 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEOXYADENOSINE; DEPSIPEPTIDE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; LUMILIXIMAB; MITOXANTRONE; MONOCLONAL ANTIBODY; NSC 6 30176; OBLIMERSEN; PENTOSTATIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; STEROID; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE;

AGE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CROSS RESISTANCE; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; FLU LIKE SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; INFECTION; MONOTHERAPY; NEUTROPENIA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PROGNOSIS; REVIEW; STRUCTURE ANALYSIS; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PURINES;

EID: 33646268635     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0013-x     Document Type: Review

References (60)

1. Redaelli A, Laskin BL, Stephens JM, et al.: The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care 2004, 13:279-287.
2. Ries LAG, Eisner MP, Kosary CL, et al.: SEER Cancer Statistics Review 1975-2001. Bethesda, MD: National Cancer Institute; 2001.
3. Dighiero G, Binet JL: When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000, 343:1799-1801.
4. Chioriazzi N, Rai KR. Ferrarini M: Mechanism of disease: chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
5. Montserrat E: Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? Hematol J 2002, 3:7-9.
6. Dohner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
7. Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
8. Hamblin TJ, Davis Z, Gardiner A. et al.: Unmutated immunoglobulin VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
9. Wagner SD, Cwynarski K: Chronic lymphocytic leukemia: new biological markers for assessing prognosis. Hematol J 2004, 5:197-201.
10. Hamblin TJ, Orchard JA, Ibbotson RE, et al.: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002, 99:1023-1029.
11. Thunberg U, Johnson A, Roos G, et al.: CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001, 97:1892-1894.
12. Rosenwald A, Alizadeh AA, Widhopf G, et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1647.
13. Chen L, Widhopf G, Huynh L, et al.: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609-4614.
14. Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764-1775.
15. Wiestner A, Rosenwald A, Barry TS, et al.: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood 2003, 101:4944-4951.
16. Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351:893-901.
17. Orchard JA, Ibbotson R, Devis Z, et al.: ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet 2004, 363:105-111.
18. Schultze JL, Donovan JW, Gribben JG: Minimal residual disease detection after myeloablative chemotherapy in chronic lymphotic leukemia. J Mol Med 1999, 77:259-265.
19. Ritgen M, Bottcher S, Dreger P, Knaba M: Evaluation of minimal residual disease in chronic lymphocytic leukemia. Haematologica Res 2005, 1(Suppl 2):5-8.
20. Magnac C, Sutton L, Cazin B, et al.: Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther 1999, 41:13-18.
21. Pfitzner T, Reiser M, Barth S, et al.: Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann Hematol 2002, 81:258-266.
22. Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23:2971-2979.
23. Robak T, Kasznicki M: Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 2002, 16:1015-1027.
24. Nicolle A, Proctor SJ, Summerfield GP: High dose chlorambucil in the treatment of lymphoid malignancies. Leuk Lymphoma 2004, 45:271-275.
25. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists Collaborative Group. J Natl Cancer Inst 1999, 91:861-868.
26. Bergmann MA, Goebeler ME, Herold M, et al.: Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005, 90:1357-1364.
27. Robak T, Korycka A, Kasznicki M, et al.: Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets 2005, 5:421-444.
28. Robak T, Blonski JZ, Kasznicki M, et al.: Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000, 96:2723-2729.
29. Rai KR, Peterson BL, Appelbaum FR, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750-1757.
30. Johnson S, Smith AG, Loffler H, et al.: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996, 347:1432-1438.
31. Leporrier M, Chevret S, Cazin B, et al.: French Cooperative Group on Chronic Lymphocytic Leukemia. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001, 98:2319-2325.
32. Jaksic B, Brugiatelli M, Suciu S, et al.: Fludarabine versus high-dose continuous chlorambucil in untreated patients with B-CLL: results of CLL1 EORTC randomized trial [abstract P 096]. Haematol Cell Ther 2000, 42:97.
33. Karlsson K, Stromberg M, Jonsson V, et al.: Cladribine (CdA), fludarabine (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia. First interim analysis of data from the international randomized phase III trial [abstract 3470]. Blood 2004, 104(Suppl 1):945a.
34. Robak T, Blonski JZ, Góra-Tybor J, et al.: Cladribine with cyclophosphamide v.s. fludarabine with cyclophosphamide as first-line treatment in chronic lymphocytic leukemia: an early report of prospective randomized study (PALG CLL3) [abstract 364]. Hematologica 2005, 90(Suppl 2):143-144.
35. Rossi JF, van Hoof A, De Boeck K, et al.: Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2004, 22:1260-1267.
36. Boogaerts MA: Oral fludarabine therapy in chronic lymphocytic leukemia - increased convenience. Hematology 2004, 5(Suppl 1):S31-S37.
37. Eichhorst B, Busch R, Hopfinger G, et al.: Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107:885-891.
38. Bosch F, Ferrer A, Lopez-Guillermo A, et al.: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol 2002, 119:976-984.
39. Robak T, Blonski JZ, Góra-Tybor J, et al.: Cladribine alone or in combination with cyclophosphamide or cyclophosphamide and mitoxantrone as first line treatment in chronic lymphocytic leukemia: an early report of prospective, randomized study [abstract 337]. Blood 2004, 104(Suppl 1):100a.
40. Weiss MA, Maslak PG, Jurcic JG, et al.: Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003, 21:1278-1284.
41. Byrd JC, Smith L, Hackbarth ML, et al.: Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003, 63:36-38.
42. O'Brien SM, Kantarjian H, Thomas DA, et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165-2170.
43. Schulz H, Klein SK, Rehwald U, et al.: Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002, 100:3115-3120.
44. Savage DG, Cohen NS, Hesdorffer CS, et al.: Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 2003, 44:477-481.
45. Byrd JC, Peterson BL, Morrison VA, et al.: Randomized phase 2 study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB9712). Blood 2003, 101:6-14.
46. Keating MJ, O'Brien S, Albitar M, et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079-4088.
47. Wierda W, O'Brien S, Wen S, et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070-4078.
48. Byrd JC, Rai K, Peterson BL, et al.: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105:49-53.
49. Osterborg A, Dyer MJ, Bunjes D, et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997, 15:1567-1574.
50. Rai KR, Freter CE, Mercier RJ, et al.: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002, 20:3891-3897.
51. Lundin J, Kimby E, Bjorkholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768-773.
52. Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554-3561.
53. Rawstron AC, Kennedy B, Moreton P, et al.: Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004, 103:2027-2031.
54. Ferrajoli A, O'Brien SM, Cortes JE, et al.: Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003, 98:773-778.
55. Lozanski G, Heerema NA, Flinn IW et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278-3281.
56. Elter T, Borchmann P, Schulz H, et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005, 23:7024-7031.
57. Mavromatis BH, Cheson BD: Novel therapies for chronic lymphocytic leukemia. Blood Rev 2004, 18:137-148.
58. Wierda WG, Kipps TJ, Keating MJ: Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:6325-6332.
59. Rai KR, Moore JO, Boyd TE, et al.: Chemotherapy with or without oblimersen sodium (Bcl-2 antisense, genasense, G3139) in advanced CLL: report of a large randomized study [abstract P94]. Leuk Lymphoma 2005, 46(Suppl 1):585.
60. Rizouli V, Gribben J: The role of stem cell transplantation in chronic lymphocytic leukemia. Semin Hematol 2004, 41:246-253.